ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers

Na Jing(Shanghai Jiao Tong University), Helen He Zhu(Shanghai Jiao Tong University), Kaiyuan Liu(Shanghai Cancer Institute), Wei‐Qiang Gao(Shanghai Jiao Tong University), Wentian Zhang(Shanghai Jiao Tong University), Xinyu Chen(Jiangsu University), Zhongzhong Ji(Shanghai Cancer Institute), Yuman He(Shanghai Jiao Tong University), Guanglei Zhuang(Shanghai Jiao Tong University), Kai Zhang(Chinese Academy of Sciences), Qi Wang(Shanghai Cancer Institute), Wei Xue(Shanghai Jiao Tong University), Pengfei Ma(Shanghai Jiao Tong University), Liancheng Fan(Shanghai Jiao Tong University), Yingchao Zhang(Shanghai Jiao Tong University), Deng Wang(Ezhou Central Hospital), Yujiao Sun(Shanghai Cancer Institute), Penghui Xu(Jiangsu Province Hospital), Wei Bao(Shanghai Cancer Institute), Lingling Xiao(Shanghai University of Traditional Chinese Medicine), Yiming Gong(Shanghai Cancer Institute), Baijun Dong(Shanghai Cancer Institute), Pengcheng Zhang(Xijing Hospital), Chaping Cheng(Shanghai Jiao Tong University), Huifang Zhao(University of Science and Technology of China), Zhixiang Xin(Shanghai Cancer Institute), Yiyi Ji(Shanghai Jiao Tong University)
Journal of Clinical Investigation
December 14, 2023
Cited by 29


Related Papers